Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 8/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18926936 | 0.81 | MKNK2 (0.39) | MKNK2PRMT5WDR77MKNK1ADORA2A | |
| Ammonia Solution, Strong SCHEMBL27463691 | 0.80 | PI4KA (0.39) | MKNK2PRMT5WDR77MKNK1PI4KA | |
| SCHEMBL2173797 | 0.79 | MKNK2 (0.40) | MKNK2PRMT5WDR77MKNK1EGFR | |
| SCHEMBL25818492 | 0.79 | MKNK2 (0.40) | MKNK2PRMT5WDR77MKNK1EGFR | |
| SCHEMBL13195335 | 0.79 | MKNK2 (0.40) | MKNK2PRMT5WDR77MKNK1ADORA2A | |
| SCHEMBL24110604 | 0.78 | HTR2C (0.47) | MKNK2EGFRHTR2AHTR2C | |
| SCHEMBL30404228 | 0.78 | HTR2C (0.52) | CYP1A2CYP2C9CYP3A4HTR2AHTR2C | |
| SCHEMBL25301570 | 0.78 | HTR2C (0.52) | CYP1A2CYP2C9CYP3A4HTR2AHTR2C | |
| SCHEMBL24110230 | 0.78 | HTR2C (0.52) | CYP1A2CYP2C9CYP3A4HTR2AHTR2C | |
| SCHEMBL8817640 | 0.77 | MKNK2 (0.39) | MKNK2PRMT5WDR77MKNK1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022272060-A1 | EP2 ANTAGONIST COMPOUNDS | RESERVOIR NEUROSCIENCE, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-11161864-B2 | Sting agonists | Venenum Biodesign, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200131209-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC | 2020-04-30 | — | — | US | disclosed |
| US-8172873-B2 | Shape memory polymers | UNIVERSITY OF ROCHESTER (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110251364-A1 | Shape Memory Polymers | NATIONAL SCIENCE FOUNDATION | 2011-10-13 | — | — | US | disclosed |
| US-7935131-B2 | Shape memory polymers | UNIVERSITY OF ROCHESTER (US) | 2011-05-03 | — | — | US | disclosed |
| US-20080177303-A1 | Shape memory polymers | ROCHESTER, UNIVERSITY OF | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131209-A1 | NOVEL STING AGONISTS | STING1, CGAS, TBK1 | MKNK2 2998/4885PRMT5 1637/4885WDR77 719/4885 |
| US-11161864-B2 | Sting agonists | STING1, IRF3, CGAS | MKNK2 2937/4885PRMT5 1409/4885WDR77 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.